Case Report

Massive Gastrointestinal Bleeding, Consequences Interactions of Apixaban, Diltiazem and Aspirin: Case Report

Abstract

Anticoagulation is the cornerstone of preventing thrombosis. Following the aging of society and the greater use of anticoagulant drugs, we see more serious complications in this group. The reduced occurrence of significant bleeding represents a notable benefit of direct oral anticoagulants (DOACs) in comparison to vitamin K antagonists. However, the unavailability of Andexanet alfa and Idarucizumab complicates the management of bleeding associated with DOACs. This case describes a 69-year-old man who presented with massive gastrointestinal bleeding, hemorrhagic shock, and loss of conciseness. He has been taking apixaban 2.5 mg twice a day, aspirin 80 mg once a day, and diltiazem 60 mg three times daily. Bleeding was controlled through transfusion of two units of fresh frozen plasma, five units of packed cell, four units of platelet, and tranexamic acid injection. Although hemorrhagic shock was successfully managed, he unfortunately passed away after three weeks of hospitalization following Ventilator-associated pneumonia and sepsis. In this case, we discuss the importance of the drug interaction of apixaban, diltiazem, and aspirin.

[1] Chen A, Stecker E, A. Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13): e017559.
[2] Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol. 2019;94(6):697-709.
[3] Abraham NS, Horsley-Silva JL. Gastrointestinal bleeding secondary to the new anticoagulants. Curr Opin Gastroenterol. 2016;32(6):474-80.
[4] Wiggins BS, Dixon DL, Neyens RR, Page RL, Gluckman TJ. Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. J Am Coll Cardiol. 2020;75(11):1341-50.
[5] Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, Hung AM, Daugherty JR, Dickson A, Murray KT. Serious Bleeding in Patients with Atrial Fibrillation Using Diltiazem with Apixaban or Rivaroxaban. J Am Med Assoc. 2024.
[6] Cook HE, Hewitt JH, Patterson EP, Randolph AE. Impact of drug interactions on major bleed rates in patients taking direct oral anticoagulants. Journal of Pharmacy Practice. 2023;36(3):600-5.
[7] Al Aseri Z, AlGahtani FH, Bakheet MF, Al-Jedai AH, Almubrik S. Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents. J Cardiovasc Pharmacol Ther. 2023; 28:10742484231202655.
[8] Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. Drug Saf. 2006; 29:79-90.
[9] Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021 Feb;14(2): e007230.
[10] Hellenbart EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag. 2017:325-42.
[11] Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63(9):891-900.
[12] Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real-world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020; 49:636-43.
[13] Grottke O, Afshari A, Ahmed A, Arnaoutoglou E, Bolliger D, Fenger-Eriksen C, von Heymann C. Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding. European J Anaesthesiol. 2024;41(5):327-50.
[14] De Marco F, Valli G, Ancona C, Ruggieri MP. Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going. Eur Heart J Suppl. 2023;25(Supplement_C):C15-9.
[15] Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker WJ, Mehran R, Messé SR. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594-622.
[16] Moia M, Squizzato A. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. Intern Emerg Med. 2019;14(8):1233-9.
[17] Morotti A, Goldstein JN. New oral anticoagulants and their reversal agents. Curr Treat Options Neurol. 2016; 18:1-5.
Files
IssueArticle in Press QRcode
SectionCase Report(s)
Keywords
Apixaban Diltiazem Aspirin Drug interactions Hemorrhagic shock DOACs
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Karballaei Mirzahosseini H, Shahriari P, Yousefi-Mazhin E, Najafi A, Mojtahedzadeh A, Mojtahedzadeh M. Massive Gastrointestinal Bleeding, Consequences Interactions of Apixaban, Diltiazem and Aspirin: Case Report. Arch Anesth & Crit Care. 2024;.